Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of micro peptide CIP2A-BP in treatment of cancer

A technology of CIP2A-BP and micropeptide, applied in the field of biomedicine, to achieve the effect of inhibiting metastasis and invasion

Active Publication Date: 2019-07-30
SUZHOU UNIV
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Previous studies have shown that TGF-β treatment can directly regulate lncRNAs at the transcriptional level, however, little is known whether TGF-β treatment can directly affect lncRNAs at the translational level

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of micro peptide CIP2A-BP in treatment of cancer
  • Application of micro peptide CIP2A-BP in treatment of cancer
  • Application of micro peptide CIP2A-BP in treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1 Micropeptide CIP2A-BP inhibits the migration and invasion of triple-negative breast cancer cells

[0040] Transwell Cell Migration and Invasion Assay: The ability of cells to migrate and invade, respectively, was assessed using a Corning Transwell insert chamber (Corning) and a BioCoat Matrigel Invasion Chamber (BD Biosciences) with 8 mm sized holes. Approximately 1.0 x 10 in 200 μl of serum-free DMEM medium 4 (migration assay) or 2.0×10 5 (Invasion Assay) Transfected cells were seeded in the upper wells; the chambers were then incubated with medium plus 20% fetal bovine serum at 37°C for 48 hours to allow cells to migrate to the lower wells. Cells that had migrated or invaded the membrane were fixed in methanol, stained with crystal violet, imaged and counted.

[0041] Wound healing experiments: Cells were seeded on ibidi cell culture inserts in 35-mm dishes and incubated at 37 °C, 5% CO 2 cultivated in. After 24 hours, the culture inserts were removed an...

Embodiment 2

[0044] Example 2 Micropeptide CIP2A-BP inhibits breast cancer metastasis and invasion in MMTV-PyMT mouse model

[0045] See Figure 2A to Figure 2F , CIP2A-BP was first transferred into C57BL / 6 mice, and then mated with MMTV-PyMT mice to generate MMTV-PyMTCIP2A-BP+ / + mice. It was found that MMTV-PyMTCIP2A-BP+ / + mice had fewer lung metastases compared with MMTV-PyMT mice. Moreover, it was found that MMTV-PyMTCIP2A-BP+ / + mice had lower expression of p-AKT compared with MMTV-PyMT primary tumors. CIP2A-BP was first transferred into C57BL / 6 mice using MM, and then mated with MMTV-PyMT mice to generate MMTV-PyMT;CIP2A-BP+ / + mice. MMTV-PyMT;CIP2A-BP+ / + mice were found to have fewer lung metastases compared to MMTV-PyMT mice ( Figure 2A ). Moreover, it was found that compared with the primary tumor of MMTV-PyMT, MMTV-PyMT; CIP2A-BP+ / + mice had lower expression of p-AKT ( Figure 2B ). Using the MMTV-PyMT mouse model, we further investigated the effect of exogenous CIP2A-BP trea...

Embodiment 3

[0046] Example 3 Low expression of the micropeptide CIP2A-BP is associated with poor survival in patients with triple-negative breast cancer

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of micro peptide CIP2A-BP in treatment of cancer. From the prospective of translating horizontal IncRNA codes, the influence of the micro peptide on the malignantbiological behaviors of breast cancer cell transferring and migration is studied. By means of treatment of the targeted micro peptide CIP2A-BP, B56 gamma subunits of the micro peptide CIP2A-BP and PP2A are competitively bound with cell cancer genes CIP2A, and therefore PP2A activity is released, activation of a PI3K / AKT / NF kappa B access is inhibited, and consequently the expression level of matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase 9 (MMP-9) and EMT induced transcription factors Snail is reduced. It is proved through in-vitro and in-vivo experiments that migration and invasion of breast cancer cells can be obviously inhibited through micro peptide CIP2A-BP, and the micro peptide CIP2A-BP has clinical application value on breast cancer.

Description

technical field [0001] The invention relates to the application of a micropeptide CIP2A-BP in treating cancer, belonging to the field of biomedicine. Background technique [0002] Triple-negative breast cancer (TNBC) is a subtype of breast cancer that accounts for 15% of all breast cancers. TNBC is negative for estrogen receptor (ER) and progesterone receptor (PR) expression and lacks HER2 amplification or overexpression. It is generally associated with more aggressive tumor behavior, including younger age of onset, shorter time to recurrence, higher risk of local and distant metastasis, and therefore lower overall survival compared with other breast cancer subtypes. Currently, there is no effective targeted therapy for TNBC. [0003] The TGF-β signaling pathway plays an important role in normal cell development and growth. Alterations in the TGF-β signaling pathway have been reported in tumorigenesis, tumor invasion and metastasis. In breast cancer, TGF-β treatment indu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/16A61P35/00
CPCA61K38/16A61P35/00
Inventor 周翊峰邓杰琼郭宾宾张征吴思奇李华
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com